Glypican-1 is a novel immunohistochemical marker to differentiate poorly differentiated squamous cell carcinoma from solid predominant adenocarcinoma of the lung.

Content Provider	Europe PMC
Author	Kai, Yuichiro Amatya, Vishwa Jeet Kushitani, Kei Kambara, Takahiro Suzuki, Rui Fujii, Yutaro Tsutani, Yasuhiro Miyata, Yoshihiro Okada, Morihito Takeshima, Yukio
Copyright Year	2021
Abstract	BackgroundThe histological classification of non-small cell lung cancer (NSCLC) is essential in determining new cancer-specific targeted therapies. However, the accurate typing of poorly differentiated is difficult, particularly for poorly differentiated squamous cell carcinoma and adenocarcinoma of the lung with limited immunohistochemical markers. Thus, novel immunohistochemical markers are required. We assumed the possibility of the immunohistochemical expression of glypican-1 in lung squamous cell carcinoma.MethodsThe microarray dataset GSE43580 from Gene Expression Omnibus database were analyzed for confirming the gene expression of glypican-1 in lung squamous cell carcinoma. We immunohistochemically investigated the use of glypican-1 as a novel positive diagnostic marker for lung squamous cell carcinoma. Glypican-1 expression in 63 cases of poorly differentiated lung squamous cell carcinoma and 60 cases of solid predominant lung adenocarcinoma was investigated by immunohistochemistry. Additionally, we compared glypican-1 expression with the expressions of p40, cytokeratin 5/6, thyroid transcription factor-1 (TTF-1), and napsin A.ResultsAll 63 cases of lung squamous cell carcinoma showed glypican-1 expression. In contrast, only 2 cases of lung adenocarcinoma showed glypican-1 expression. The sensitivity, specificity, and diagnostic accuracy of glypican-1 expression for differentiating lung squamous cell carcinoma from lung adenocarcinoma were 100%, 96.7%, and 98.4%, respectively. These were similar to those of p40 and significantly better than those of CK 5/6.ConclusionsWe recommend the use of glypican-1 as an additional positive marker of lung squamous cell carcinoma.
ISSN	22186751
Journal	Translational Lung Cancer Research
Volume Number	10
PubMed Central reference number	PMC7947391
Issue Number	2
PubMed reference number	33718020
e-ISSN	22264477
DOI	10.21037/tlcr-20-857
Language	English
Publisher	AME Publishing Company
Publisher Date	2021-02-01
Access Restriction	Open
Rights License	Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0. 2021 Translational Lung Cancer Research. All rights reserved.
Subject Keyword	Glypican-1 immunohistochemistry lung squamous cell carcinoma lung adenocarcinoma
Content Type	Text
Resource Type	Article
Subject	Oncology